Drug
Tamibarotene clinical trials
Also written Am80.
- studies test it
- 14
- open now
- 3
- in phase 3
- 2
- first study started
- 2006
Keep track of what changes. Save the tamibarotene studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
14 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2021 | 3 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 12
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 7
Nagoya University (3) · CytRx (2) · Syros Pharmaceuticals (2) · Rege Nephro Co., Ltd. (1) · Zeria Pharmaceutical (1) · R&R Inc. (1) · St. Marianna University School of Medicine (1) · Northwestern University (1)
Often tested with
Tested in the same studies.
Gemcitabine (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Arsenic Trioxide (1)
Studies
Open first, then newest update. How each study uses tamibarotene is read from its arms, and is right about nine times in ten.
Testing it · 14
- The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)Not yet recruitingPhase 2Nagoya UniversityNCT07855692Written as Tamibarotene
- Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial CarcinomaRecruitingPhase 2Nagoya UniversityNCT06983210Written as Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy
- Investigator-initiated Clinical Trial of MIKE-1RecruitingPhase 1/2Nagoya UniversityNCT05064618Written as Am80
- Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)TerminatedPhase 2/3St. Marianna University School of MedicineNCT01343355Written as Tamibarotene
- Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic SyndromeTerminatedPhase 3Syros PharmaceuticalsNCT04797780Written as Tamibarotene
- Study of Tamibarotene in Patients With ADPKDActive, not recruitingPhase 2Rege Nephro Co., Ltd.NCT06289998Written as Tamibarotene
- Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)TerminatedPhase 2Syros PharmaceuticalsNCT04905407Written as Tamibarotene
- Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic LeukemiaTerminatedPhase 1Northwestern UniversityNCT00985530Written as Tamibarotene
- First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung CancerTerminatedPhase 2CytRxNCT01337154Written as Tamibarotene
- Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APLCompletedPhase 2CytRxNCT00520208Written as Tamibarotene
- Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)CompletedPhase 1/2Zeria PharmaceuticalNCT00731445Written as Z-208
- Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's DiseaseStatus unknownPhase 2Osaka City UniversityNCT01120002Written as Tamibarotene
- Efficacy and Safety of Tamibarotene(AM80) for Lupus NephritisStatus unknownPhase 2Kinki UniversityNCT01226147Written as Tamibarotene
- Phase II Study of RR110 in Patients With Active Crohn's DiseaseCompletedPhase 2R&R Inc.NCT00417391Written as RR110 (Tamibarotene)
Given in every arm · 2 — tamibarotene is usual care beside what is tested
- A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedPhase 2Syros PharmaceuticalsNCT02807558Written as Tamibarotene
- Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic LeukemiaWithdrawnPhase 1/2M.D. Anderson Cancer CenterNCT06085638Written as Tamibarotene
Codes
What other systems call tamibarotene · ClinicalTrials.gg INT003463
- MeSH (NLM) C061133tamibaroteneOne source NLM
- UNII (FDA) 08V52GZ3H9TAMIBAROTENEConfirmed FDA, NLM, Wikidata
- Wikidata Q7681221tamibaroteneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71025TamibaroteneOne source FDA
- DrugBank DB04942One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C061133 | tamibarotene | One source NLM |
| UNII (FDA) | 08V52GZ3H9 | TAMIBAROTENE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7681221 | tamibarotene | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71025 | Tamibarotene | One source FDA |
| DrugBank | DB04942 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.